<DOC>
	<DOCNO>NCT01897532</DOCNO>
	<brief_summary>The aim study investigate longterm impact cardiovascular morbidity , mortality renal function treatment linagliptin select population patient T2DM compare outcome placebo , background standard care .</brief_summary>
	<brief_title>Cardiovascular Renal Microvascular Outcome Study With Linagliptin Patients With Type 2 Diabetes Mellitus ( CARMELINA )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Documented diagnosis T2DM visit 1 ( screen ) . 2 . Male female patient drugna√Øve pretreated antidiabetic background medication , exclude treatment GLP1 receptor agonist , DPP4 inhibitor SGLT2 inhibitor = &gt; consecutive 7 day . 3 . Stable antidiabetic background medication ( unchanged daily dose ) least 8 week prior randomization . If insulin part background therapy , average daily insulin dose change 10 % within 8 week prior randomization compare daily insulin dose randomization . 4 . HbA1c = &gt; 6.5 % &lt; = 10.0 % Visit 1 ( screen ) 5 . Age = &gt; 18 year Visit 1 ( screen ) . For Japan : Age = &gt; 20 year Visit 1 6 . Body Mass Index ( BMI ) &lt; = 45 kg/m2 Visit 1 ( screen ) 7 . Signed date write informed consent date Visit 1 ( screen ) accordance Good Clinical Practice ( GCP ) local legislation prior study related procedure 8 . High risk CV event define : 1 ) albuminuria ( micro macro ) previous macrovascular disease and/or 2 ) impair renal function predefined UACR Exclusion criterion : 1 . Type 1 diabetes mellitus . 2 . Treatment ( = &gt; 7 consecutive day ) GLP1 receptor agonist , DPP4 inhibitor SGLT2 inhibitor prior inform consent . Note : This also include clinical trial antidiabetic drug provide patient . 3 . Active liver disease impair hepatic function , define serum level either ALT ( SGPT ) , AST ( SGOT ) , alkaline phosphatase ( AP ) = &gt; 3 x upper limit normal ( ULN ) determine Visit 1 . 4. eGFR &lt; 15 ml/min ( severe renal impairment ESRD , MDRD formula ) , determine screen Visit 1 and/or need maintenance dialysis . 5 . Any previous ( plan within next 12 month ) bariatric surgery ( open laparoscopic ) intervention ( gastric sleeve ) . 6 . Preplanned coronary artery revascularisation ( PCI , CABG ) previous PCI and/or CABG &lt; = 2 month prior inform consent . 7 . Known hypersensitivity allergy investigational product excipients . 8 . Any previous current alcohol drug abuse would interfere trial participation opinion investigator . 9 . Participation another trial investigational drug ongoing within 2 month prior visit 1 ( screen ) . 10 . Premenopausal woman ( last menstruation = 1 year prior informed consent ) nursing pregnant , childbearing potential practicing acceptable method birth control ( acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence ( allow local authority ) , double barrier method vasectomise partner ) plan continue use acceptable method birth control throughout study agree submit periodic pregnancy test participation trial . 11 . Patients consider unreliable investigator concerning requirement follow study and/or compliance study drug administration , life expectancy le 5 year nonCV cause , cancer nonmelanomaskin cancer within last 3 year , condition mention opinion investigator , would allow safe participation study . 12 . Acute coronary syndrome ( ACS ) , diagnose &lt; = 2 month prior visit 1 ( screen ) . 13 . Stroke TIA &lt; = 3 month prior visit 1 ( screen ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>